Compare RYM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYM | PRPO |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 32.4M |
| IPO Year | 2021 | N/A |
| Metric | RYM | PRPO |
|---|---|---|
| Price | $21.06 | $24.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.7K | 8.7K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,303,000.00 | ★ $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1338.92 | 30.95 |
| 52 Week Low | $13.22 | $3.90 |
| 52 Week High | $53.65 | $28.50 |
| Indicator | RYM | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 52.79 |
| Support Level | $17.66 | $23.77 |
| Resistance Level | $19.28 | $25.64 |
| Average True Range (ATR) | 1.48 | 1.47 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 42.26 | 28.79 |
Rythm Inc is a USA Based company. The Company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.